When Scleroderma Meets Vasculitis: A Rare Overlap with Treatment Implications
A multicenter retrospective study has characterized the rare but significant overlap between systemic sclerosis (SSc) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The research, involving 30 patients across 18 French centers, found that SSc preceded AAV in all cases, with the majority presenting as limited cutaneous SSc. A striking 80% of patients had interstitial lung disease (ILD), predominantly of a fibrosing nonspecific interstitial pneumonia pattern. The vasculitis was overwhelmingly microscopic polyangiitis (90%) with myeloperoxidase (MPO)-ANCA positivity. Critically, the study reports that standard vasculitis treatments, including high-dose glucocorticoids combined with cyclophosphamide or rituximab, were effective and did not worsen SSc outcomes, with no observed cases of scleroderma renal crisis.
Why it might matter to you: This research provides crucial clinical guidance for managing a complex, high-risk patient population where treatment decisions are often complicated by concerns over exacerbating underlying scleroderma. It suggests that aggressive immunosuppression for vasculitis can be pursued without necessarily triggering a scleroderma renal crisis, a key consideration for rheumatologists. The findings underscore the importance of screening for MPO-ANCA in SSc patients, particularly those with anti-Scl70 antibodies and fibrosing ILD, to identify this overlap syndrome early.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
